The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.
July 26th 2024
These data highlighted new findings on the experiences of children aged 6 to 11 with uncontrolled type 2 asthma treated with dupilumab.
High Oral Corticosteroid Dose and Exposure in Asthma
May 29th 2024The panel addresses the issue of patients being exposed to high levels of oral corticosteroids (OCS) without realizing it, as various prescribers can administer steroids. They also discuss the essential questions healthcare professionals should ask to comprehend a patient's total OCS exposure and provide a definition of high OCS use.
Moderate/Severe/Uncontrolled Asthma Classification
May 15th 2024The key opinion leaders deliberate on the criteria used to classify a patient as having moderate or severe asthma, as well as the factors that determine when a patient's asthma is deemed uncontrolled—including the use of combination therapy and daily symptoms.
Type 2 Inflammation and Biomarkers in Asthma
May 15th 2024The panelists explore the significance of type 2 inflammation in asthma, including its role and associated markers, while also delving into their approach to assessing patients whose asthma is triggered or worsened by allergies, examining markers beyond IgE and noting the frequency of patients presenting with asthma symptoms during allergy season without actually having allergic asthma.
Boehringer Ingelheim Announces $35 Monthly Price Cap on Inhalers for Asthma, COPD Patients
March 7th 2024On March 07, 2024, Boehringer Ingelheim announced it would be instituting a $35 per month out-of-pocket cost cap for its portfolio of inhaler products, with this cap going into effect on June 01, 2024.
Severe Asthma Exacerbations: Spotlighting Trends Before and After COVID-19 Restrictions
The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.
Prevalence of Anxiety, Depression Assessed for Pediatric High-Risk Asthma Patients
This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.
Tezepelumab Helps to Stabilize Bronchial Epithelial Immune Response to Respiratory Viruses
Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.
Prediction Model Effective for Community-Acquired Pneumonia in Those with Acute Asthma Exacerbations
This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.
How Did Canadian Wildfires Impact Emergency Department Visits for Asthma Syndrome in New York?
New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.